PHLDA2 and nonpapillary renal cell carcinoma: Our results suggested that elevated PHLDA2 expression could be served as an independent high-risk prognostic factor, predicting worse therapeutic efficacy of ICI plus anti-angiogenic agent combination therapy in ccRCC.